Arcoxia is easy on the stomach, but it’s tough on the heart.
|
Defibrillator sales’ irregular beat; Merck wins Vioxx Case; women’s drugs: $63B by 2010
|
Ibuprofen and other household remedies may pose risks.
|
Drug company must pay $4.5 million to one of two plaintiffs for causing his heart attack.
|
A study claims Celebrex should not receive preferential treatment over Vioxx.
|
A new study concludes that Celebrex is no safer than similar drugs that have been pulled from the market.
|
As big pharma’s blockbuster business model falters, personalized drugs start to gain traction.
|
Drug giant plans to offer new drugs, but will also take another dose of cost-cutting as it fends off thousands of Vioxx suits.
|
The jury fails to reach a verdict in the first federal case involving problems linked to Merck’s painkiller.
|
Influential medical journal says drug giant submitted false data about heart problems linked to its pain drug Vioxx.
|
Drug maker is closing five plants in restructuring effort to deal with ongoing Vioxx litigation and other challenges.
|
U.S. and E.U. authorities investigate reports of suicides of Japanese teenagers who took flu treatment.
|
A jury finds the pharma giant gave doctors adequate warning about Vioxx's risks.
|
Pharma startup to develop clinical trials for drugs used in other countries.
|
The global counterfeit medicine industry is big and growing fast, reaping high margins and presenting great risk to public health. Legit firms are forced to adapt, and that means opportunity for those in the know.
|
Search titan builds massive space inside communications nerve center; Vonage seeks sale; BT starts new life; drug makers launch clinical trials site.
|
The British pharma giant’s CCR5 antagonist has proven toxic in mid-stage trials.
|
A new study suggests that a chemical relation to Pfizer’s COX-2 inhibitor could become a treatment for multiple myeloma.
|
The first Vioxx verdict aside, analysts looking to additional indicators to gauge the power of the tidal wave coming at Merck.
|
Merck’s market cap tumbles $5.17 billion after a jury awards $253 million in the first case focused on the painkiller.
|
Page
1
of
2
|